QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
NASDAQ:PRQR

ProQR Therapeutics (PRQR) Stock Forecast, Price & News

$0.68
+0.02 (+3.03%)
(As of 05/17/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.65
$0.68
50-Day Range
$0.56
$1.06
52-Week Range
$0.53
$9.09
Volume
341,590 shs
Average Volume
1.63 million shs
Market Capitalization
$48.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.97
30 days | 90 days | 365 days | Advanced Chart
Receive PRQR News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ProQR Therapeutics logo

About ProQR Therapeutics

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as ProQR Therapeutics VIII B.V. for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRQR
Fax
N/A
Employees
1,504
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.60 million
Book Value
$1.88 per share

Profitability

Net Income
$-72.90 million
Net Margins
-2,469.79%
Pretax Margin
-4,546.50%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$48.41 million
Optionable
Optionable

Company Calendar

Last Earnings
2/24/2022
Today
5/17/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.77 out of 5 stars

Medical Sector

837th out of 1,426 stocks

Pharmaceutical Preparations Industry

409th out of 680 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -













ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

Is ProQR Therapeutics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ProQR Therapeutics stock.
View analyst ratings for ProQR Therapeutics
or view top-rated stocks.

Are investors shorting ProQR Therapeutics?

ProQR Therapeutics saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 1,150,000 shares, a drop of 28.1% from the April 15th total of 1,600,000 shares. Based on an average daily volume of 2,030,000 shares, the short-interest ratio is currently 0.6 days. Approximately 2.1% of the company's shares are short sold.
View ProQR Therapeutics' Short Interest
.

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for ProQR Therapeutics
.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) issued its earnings results on Thursday, February, 24th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.04. The biopharmaceutical company earned $0.27 million during the quarter, compared to the consensus estimate of $0.90 million. ProQR Therapeutics had a negative net margin of 2,469.79% and a negative trailing twelve-month return on equity of 51.75%.
View ProQR Therapeutics' earnings history
.

What price target have analysts set for PRQR?

8 analysts have issued 12 month target prices for ProQR Therapeutics' shares. Their forecasts range from $2.00 to $19.00. On average, they expect ProQR Therapeutics' stock price to reach $7.43 in the next year. This suggests a possible upside of 994.0% from the stock's current price.
View analysts' price targets for ProQR Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are ProQR Therapeutics' key executives?
ProQR Therapeutics' management team includes the following people:
  • Mr. Daniel Anton de Boer, Founder, CEO & Member of Management Board (Age 39, Pay $761.74k)
  • Ms. Theresa Marie Heggie, Chief Operating Officer (Age 62, Pay $39.23k)
  • Mr. Gerard Platenburg, Co-Founder & Chief Innovation Officer (Age 58)
  • Ms. Smital Shah M.B.A., Chief Bus. & Financial Officer (Age 46)
  • Dr. Naveed K. Shams M.D., Ph.D., Chief Scientific Officer (Age 66)
  • Ms. Sarah Cue Kiely, VP of Investor Relations & Corp. Communications
  • Ms. Sheila Sponselee, VP of HR
  • Mr. Bart Klein, Sr. VP of Intellectual Property
  • Ms. Bianca Matthee, Head of Manufacturing and Pharmaceutics
  • Mr. Aniz Girach M.D., Chief Medical Officer (Age 55)
What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Privium Fund Management B.V. (10.45%), Wellington Management Group LLP (4.33%), M28 Capital Management LP (1.41%), JPMorgan Chase & Co. (1.37%), Goldman Sachs Group Inc. (1.09%) and Renaissance Technologies LLC (0.85%).

Which institutional investors are selling ProQR Therapeutics stock?

PRQR stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Gilder Gagnon Howe & Co. LLC, Wellington Management Group LLP, Belvedere Trading LLC, Mirae Asset Global Investments Co. Ltd., and Simplex Trading LLC.

Which institutional investors are buying ProQR Therapeutics stock?

PRQR stock was bought by a variety of institutional investors in the last quarter, including M28 Capital Management LP, Renaissance Technologies LLC, Privium Fund Management B.V., JPMorgan Chase & Co., Prosight Management LP, XTX Topco Ltd, Monaco Asset Management SAM, and BlackRock Inc..

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $0.68.

How much money does ProQR Therapeutics make?

ProQR Therapeutics has a market capitalization of $48.41 million and generates $1.60 million in revenue each year. The biopharmaceutical company earns $-72.90 million in net income (profit) each year or ($1.07) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

ProQR Therapeutics employs 1,504 workers across the globe.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is www.proqr.com.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at [email protected].

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.